Authors: ALEXANDER T. BAKERHTTPS://ORCID.ORG/0000-0001-8232-0531RYAN J. BOYDHTTPS://ORCID.ORG/0000-0002-6704-8696DAIPAYAN SARKARHTTPS://ORCID.ORG/0000-0002-4167-2108ALICIA TEIJEIRA-CRESPOCHUN KIT CHANEMILY BATESHTTPS://ORCID.ORG/0000-0003-1378-6981KASIM WARAICHHTTPS://ORCID.ORG/0000-0002-2927-7383JOHN VANTHTTPS://ORCID.ORG/0000-0003-0627-4603ERIC WILSONHTTPS://ORCID.ORG/0000-0002-4104-1445[…]MITESH J. BORADHTTPS://ORCID.ORG/0000-0003-2700-2658 +16 authors Authors Info & Affiliations
Abstract
Vaccines derived from chimpanzee adenovirus Y25 (ChAdOx1), human adenovirus type 26 (HAdV-D26), and human adenovirus type 5 (HAdV-C5) are critical in combatting the severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic. As part of the largest vaccination campaign in history, ultrarare side effects not seen in phase 3 trials, including thrombosis with thrombocytopenia syndrome (TTS), a rare condition resembling heparin-induced thrombocytopenia (HIT), have been observed. This study demonstrates that all three adenoviruses deployed as vaccination vectors versus SARS-CoV-2 bind to platelet factor 4 (PF4), a protein implicated in the pathogenesis of HIT. We have determined the structure of the ChAdOx1 viral vector and used it in state-of-the-art computational simulations to demonstrate an electrostatic interaction mechanism with PF4, which was confirmed experimentally by surface plasmon resonance. These data confirm that PF4 is capable of forming stable complexes with clinically relevant adenoviruses, an important step in unraveling the mechanisms underlying TTS.
For Detailed Study Information: https://www.science.org/doi/10.1126/sciadv.abl8213